Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
2006 1
2007 2
2012 1
2013 1
2014 2
2015 2
2016 2
2017 3
2018 2
2019 4
2020 3
2022 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline.
Brown RJ, Araujo-Vilar D, Cheung PT, Dunger D, Garg A, Jack M, Mungai L, Oral EA, Patni N, Rother KI, von Schnurbein J, Sorkina E, Stanley T, Vigouroux C, Wabitsch M, Williams R, Yorifuji T. Brown RJ, et al. J Clin Endocrinol Metab. 2016 Dec;101(12):4500-4511. doi: 10.1210/jc.2016-2466. Epub 2016 Oct 6. J Clin Endocrinol Metab. 2016. PMID: 27710244 Free PMC article. Review.
This practice guideline summarizes the diagnosis and management of lipodystrophy syndromes not associated with HIV or injectable drugs. ...Diet is essential for the management of metabolic complications of lipodystrophy. Metreleptin therapy is effective for m …
This practice guideline summarizes the diagnosis and management of lipodystrophy syndromes not associated with HIV or injectable drug …
Treatment Options for Lipodystrophy in Children.
Mainieri F, Tagi VM, Chiarelli F. Mainieri F, et al. Front Endocrinol (Lausanne). 2022 May 4;13:879979. doi: 10.3389/fendo.2022.879979. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35600578 Free PMC article. Review.
Given the evidence of leptin deficiency in lipodystrophy syndromes, leptin replacement therapy has been considered as a treatment option. ...However, further research is being conducted for new and different therapeutic agents, especially helpful for the trea …
Given the evidence of leptin deficiency in lipodystrophy syndromes, leptin replacement therapy has been considered as a treatm …
Clinical Features and Management of Non-HIV-Related Lipodystrophy in Children: A Systematic Review.
Gupta N, Asi N, Farah W, Almasri J, Barrionuevo P, Alsawas M, Wang Z, Haymond MW, Brown RJ, Murad MH. Gupta N, et al. J Clin Endocrinol Metab. 2017 Feb 1;102(2):363-374. doi: 10.1210/jc.2016-2271. J Clin Endocrinol Metab. 2017. PMID: 27967300 Free PMC article. Review.
CONTEXT: Lipodystrophy syndromes are characterized by generalized or partial absence of adipose tissue. ...In acquired partial lipodystrophy (APL), upper limbs were involved while lower limbs were spared. ...
CONTEXT: Lipodystrophy syndromes are characterized by generalized or partial absence of adipose tissue. ...In acquired part …
Development of Antisense Oligonucleotide Gapmers for the Treatment of Dyslipidemia and Lipodystrophy.
Aslesh T, Yokota T. Aslesh T, et al. Methods Mol Biol. 2020;2176:69-85. doi: 10.1007/978-1-0716-0771-8_5. Methods Mol Biol. 2020. PMID: 32865783 Review.
With the approval of splice-switching antisense oligonucleotide (AO) therapy for nusinersen and eteplirsen for the treatment of spinal muscular atrophy (SMA) and Duchenne muscular dystrophy (DMD), several modified AOs are now being evaluated in clinical trials for the trea …
With the approval of splice-switching antisense oligonucleotide (AO) therapy for nusinersen and eteplirsen for the treatment of spina …
Metreleptin Treatment in Patients with Non-HIV Associated Lipodystrophy.
Akinci G, Akinci B. Akinci G, et al. Recent Pat Endocr Metab Immune Drug Discov. 2015;9(2):74-8. doi: 10.2174/1574892811666151111142554. Recent Pat Endocr Metab Immune Drug Discov. 2015. PMID: 26556498 Review.
Recently, metreleptin, a recombinant human leptin analog, has been approved for the treatment of patients with generalized lipodystrophy. Leptin is an adipokine which has a fundamental role in glucose and lipid homeostasis. ...Limited data has also suggested that metrelept …
Recently, metreleptin, a recombinant human leptin analog, has been approved for the treatment of patients with generalized lipodystrophy …
Impact of Combined Baricitinib and FTI Treatment on Adipogenesis in Hutchinson-Gilford Progeria Syndrome and Other Lipodystrophic Laminopathies.
Hartinger R, Lederer EM, Schena E, Lattanzi G, Djabali K. Hartinger R, et al. Cells. 2023 May 9;12(10):1350. doi: 10.3390/cells12101350. Cells. 2023. PMID: 37408186 Free PMC article.
Hutchinson-Gilford progeria syndrome (HGPS) is a rare genetic disease that causes premature aging symptoms, such as vascular diseases, lipodystrophy, loss of bone mineral density, and alopecia. HGPS is mostly linked to a heterozygous and de novo mutation in the LMNA gene ( …
Hutchinson-Gilford progeria syndrome (HGPS) is a rare genetic disease that causes premature aging symptoms, such as vascular diseases, li …
Dunnigan lipodystrophy syndrome: French National Diagnosis and Care Protocol (PNDS; Protocole National de Diagnostic et de Soins).
Mosbah H, Donadille B, Vatier C, Janmaat S, Atlan M, Badens C, Barat P, Béliard S, Beltrand J, Ben Yaou R, Bismuth E, Boccara F, Cariou B, Chaouat M, Charriot G, Christin-Maitre S, De Kerdanet M, Delemer B, Disse E, Dubois N, Eymard B, Fève B, Lascols O, Mathurin P, Nobécourt E, Poujol-Robert A, Prevost G, Richard P, Sellam J, Tauveron I, Treboz D, Vergès B, Vermot-Desroches V, Wahbi K, Jéru I, Vantyghem MC, Vigouroux C. Mosbah H, et al. Orphanet J Rare Dis. 2022 Apr 19;17(Suppl 1):170. doi: 10.1186/s13023-022-02308-7. Orphanet J Rare Dis. 2022. PMID: 35440056 Free PMC article.
Dunnigan syndrome, or Familial Partial Lipodystrophy type 2 (FPLD2; ORPHA 2348), is a rare autosomal dominant disorder due to pathogenic variants of the LMNA gene. ...Overall, the management of patients with Dunnigan syndrome requires the collaboration of several he …
Dunnigan syndrome, or Familial Partial Lipodystrophy type 2 (FPLD2; ORPHA 2348), is a rare autosomal dominant disorder due to …
The Chylomicronemia Syndrome Is Most Often Multifactorial: A Narrative Review of Causes and Treatment.
Chait A, Eckel RH. Chait A, et al. Ann Intern Med. 2019 May 7;170(9):626-634. doi: 10.7326/M19-0203. Epub 2019 Apr 30. Ann Intern Med. 2019. PMID: 31035285 Review.
It may result from 1 of 3 conditions: the presence of secondary forms of hypertriglyceridemia concurrent with genetic causes of hypertriglyceridemia, termed multifactorial chylomicronemia syndrome (MFCS); a deficiency in the enzyme lipoprotein lipase and some associated proteins, …
It may result from 1 of 3 conditions: the presence of secondary forms of hypertriglyceridemia concurrent with genetic causes of hypertriglyc …
Lipodystrophies in non-insulin-dependent children: Treatment options and results from recombinant human leptin therapy.
Calcaterra V, Magenes VC, Rossi V, Fabiano V, Mameli C, Zuccotti G. Calcaterra V, et al. Pharmacol Res. 2023 Jan;187:106629. doi: 10.1016/j.phrs.2022.106629. Epub 2022 Dec 22. Pharmacol Res. 2023. PMID: 36566927 Free article. Review.
Lipodystrophy is a general definition containing different pathologies which, except for those observed in insulin-treated subjects falling outside the scope of this paper, are characterized by total or partial lack of body fat, that, according to the amount of miss …
Lipodystrophy is a general definition containing different pathologies which, except for those observed in insulin-treated subjects f …
Volanesorsen in the Treatment of Familial Chylomicronemia Syndrome or Hypertriglyceridaemia: Design, Development and Place in Therapy.
Esan O, Wierzbicki AS. Esan O, et al. Drug Des Devel Ther. 2020 Jul 6;14:2623-2636. doi: 10.2147/DDDT.S224771. eCollection 2020. Drug Des Devel Ther. 2020. PMID: 32753844 Free PMC article. Review.
There are few current options for its long-term management. The only universal long-term therapy is restriction of total dietary fat intake to <10-15% of daily calories (15 to 20g per day). ...Other genetic syndromes associated with hypertriglyceridaemia include familia …
There are few current options for its long-term management. The only universal long-term therapy is restriction of total dietary fat …
25 results